ARROWHEAD PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2024 · Filed Feb 10, 2025
ARWR$49.00-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except per share amounts)
| Three Months Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenue | $2,500 | $3,551 |
| Operating expenses: | ||
| Research and development | 137,002 | 116,491 |
| General and administrative | 26,910 | 23,605 |
| Total operating expenses | 163,912 | 140,096 |
| Operating loss | (161,412) | (136,545) |
| Other income (expense): | ||
| Interest income | 7,602 | 2,802 |
| Interest expense | (21,646) | (5,367) |
| Other, net | 341 | 421 |
| Total other expense | (13,703) | (2,144) |
| Loss before income tax expense and noncontrolling interest | (175,115) | (138,689) |
| Income tax expense (benefit) | 103 | (3,313) |
| Net loss including noncontrolling interest | $(175,218) | $(135,376) |
| Net loss attributable to noncontrolling interest, net of tax | (2,133) | (2,512) |
| Net loss attributable to Arrowhead Pharmaceuticals, Inc. | $(173,085) | $(132,864) |
| Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.: | ||
| Basic | $(1.39) | $(1.24) |
| Diluted | $(1.39) | $(1.24) |
| Weighted-average shares used in calculating | ||
| Basic | 124,848 | 107,415 |
| Diluted | 124,848 | 107,415 |
| Other comprehensive loss, net of tax: | ||
| Unrealized (losses) gains on available-for-sale securities | (507) | 1,909 |
| Foreign currency translation adjustments | (106) | 58 |
| Comprehensive loss | $(175,831) | $(133,409) |
Consolidated Statements of Stockholders’ Equity
(in thousands)
| CommonStock | Amount ($) | AdditionalPaid-InCapital | Accumulated Other Comprehensive Income | AccumulatedDeficit | Non-controlling Interest | Total | |
|---|---|---|---|---|---|---|---|
| Balance at September 30, 2024 | 124,376 | $217 | $1,806,000 | $4,750 | $(1,625,523) | $5,619 | $191,063 |
| Stock-based compensation | — | — | 15,209 | — | — | — | 15,209 |
| Exercise of stock options | 70 | — | 634 | — | — | — | 634 |
| Common stock - restricted stock units vesting | 209 | — | — | — | — | — | — |
| Pre-funded warrants | 917 | 1 | 24,999 | — | — | — | 25,000 |
| Foreign currency translation adjustments | — | — | — | (106) | — | — | (106) |
| Unrealized gains on available-for-sale securities | — | — | — | (507) | — | — | (507) |
| Net loss | — | — | — | — | (173,085) | (2,133) | (175,218) |
| Balance at December 31, 2024 | 125,572 | $218 | $1,846,842 | $4,137 | $(1,798,608) | $3,486 | $56,075 |
| CommonStock | Amount ($) | AdditionalPaid-InCapital | Accumulated Other Comprehensive Loss | AccumulatedDeficit | Non-controlling Interest | Total | |
|---|---|---|---|---|---|---|---|
| Balance at September 30, 2023 | 107,312 | $200 | $1,300,395 | $(3,222) | $(1,026,030) | $15,819 | $287,162 |
| Stock-based compensation | — | — | 19,694 | — | — | — | 19,694 |
| Exercise of stock options | 34 | — | 267 | — | — | — | 267 |
| Common stock - restricted stock units vesting | 154 | — | — | — | — | — | — |
| Foreign currency translation adjustments | — | — | — | 58 | — | — | 58 |
| Unrealized losses on available-for-sale securities | — | — | — | 1,909 | — | — | 1,909 |
| Net loss | — | — | — | — | (132,864) | (2,512) | (135,376) |
| Balance at December 31, 2023 | 107,500 | $200 | $1,320,356 | $(1,255) | $(1,158,894) | $13,307 | $173,714 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.